We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / CNS PHARMACEUTICALS
CNS_PHARMA_METAS_SERVICE_ALT

CNS PHARMACEUTICALS

Lesvi offers one of the most comprehensive product portfolios in CNS pharmaceuticals.
12
Product Indication Dosage form Strength
Methocarbamol Muscle spasms, pain Film-coated tablets 1.5 mg
Olanzapine Psychosis, schizophrenia Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg
Olanzapine Psychosis, schizophrenia Orodispersable tablets 5, 10, 15 and 20 mg
Pipamperone Psychosis, schizophrenia Tablets 40 and 120 mg
Pramipexol Parkinson's Tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg
Pregabaline Neuropathic pain Tablets 25, 50, 75, 100, 150, 200, 225 and 300 mg
Pyridostigmine Myasthenia gravis Film-coated tablets 60 mg
Quetiapine Psychosis, schizophrenia, bipolar disoder Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg
Quetiapine Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
Rasagiline Parkinson's Tablets 1 mg
Risperidone Psychosis, schizophrenia, bipolar disoder Film-coated tablets 0.5, 1, 2, 3, 4 and 6 mg
Rotigotine Parkinson's Patches 1, 2, 3, 4, 6 and 8 mg/24h
Sodium Oxybate Narcolepsy Oral solution 500 mg/ml
Sulpiride Psychosis, schizophrenia Tablets 50, 100 and 200 mg
Sultiame [S] Epilepsy, convulsions Film-coated tablets 50, 100 and 200 mg
Tolcapone Parkinson's Film-coated tablets 100 mg
Valproate Epilepsy Oral solution 60 mg/ml and 300 mg/ml
Zonisamide Epilepsy Hard capsules 25, 50 and 100 mg
FDF PRODUCT PORTFOLIO

[S] Singular Generics

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.